Mineralys Therapeutics, Inc. (MLYS)
| Market Cap | 2.26B +132.7% |
| Revenue (ttm) | n/a |
| Net Income | -151.78M |
| EPS | -2.02 |
| Shares Out | 82.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 964,338 |
| Open | 27.29 |
| Previous Close | 27.27 |
| Day's Range | 26.77 - 27.69 |
| 52-Week Range | 12.59 - 47.65 |
| Beta | 0.48 |
| Analysts | Strong Buy |
| Price Target | 48.67 (+77.76%) |
| Earnings Date | May 6, 2026 |
About MLYS
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Minera... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price target is $48.67, which is an increase of 77.76% from the latest price.
News
Mineralys Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Lorundrostat’s NDA was accepted in Q1, with robust clinical data supporting its use in resistant hypertension. Launch preparations are underway, focusing on key prescribers and payer engagement, while international commercialization will rely on partnerships. Cash reserves support operations into 2028.
Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Mineralys Therapeutics (MLYS) to $42 from $49 and keeps a Buy rating on the shares.
Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)
“We continue to make strong progress advancing lorundrostat toward potential approval, moving closer towards our goal of delivering what we believe has the potential to be a best-in-class aldosterone ...
Mineralys Therapeutics Earnings Call Transcript: Q1 2026
FDA accepted the NDA for lorundrostat, supported by robust clinical data, with a PDUFA date set for December 2026. Cash reserves remain strong, and operational focus is on commercial launch readiness and strategic partnerships. Significant market opportunity exists in resistant hypertension.
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities ...
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities ...
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbiditie...
Mineralys Therapeutics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Mineralys Therapeutics (MLYS) with a Buy rating and no price target The company’s lorundrostat has broad, blockbuster potential in uncontrolled and resistant hypertensio...
Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board
Immunic (IMUX) announced the appointment of Jon Congleton to its board of directors, effective March 27. Congleton currently serves as CEO and member of the board of directors of Mineralys…
Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer
Mineralys Therapeutics (MLYS) announced the appointment of Jeffrey Munsie as chief legal officer. Most recently, he served as chief legal officer and Secretary at Orbital Therapeutics, where he oversa...
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbiditie...
Mineralys Therapeutics price target raised to $51 from $46 at BofA
BofA raised the firm’s price target on Mineralys Therapeutics (MLYS) to $51 from $46 and keeps a Buy rating on the shares following some corporate updates on the clinical development…
Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)
“Mineralys had a transformational year in 2025, defined by significant clinical progress and key regulatory milestones,” said Jon Congleton, Chief Executive Officer of Mineralys Therapeutics (MLYS). “...
Mineralys Therapeutics Earnings Call Transcript: Q4 2025
FDA accepted the NDA for lorundrostat, setting a PDUFA date of December 22, 2026. Strong clinical results and a robust cash position support launch preparations, with ongoing payer engagement and expanded medical communications. Net loss narrowed year-over-year as R&D spending declined.
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
– Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
Mineralys Therapeutics Inc options imply 6.5% move in share price post-earnings
Pre-earnings options volume in Mineralys Therapeutics (MLYS) Inc is normal with calls leading puts 5:1. Implied volatility suggests the market is anticipating a move near 6.5%, or 0c, after results…
Mineralys Therapeutics announces FDA acceptance of lorundrostat NDA
Mineralys Therapeutics (MLYS) announced that the FDA has accepted the new drug application, or NDA, for lorundrostat for the treatment of adult patients with hypertension in combination with other ant...
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
– The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction ...
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbiditie...
Mineralys Therapeutics Inc options imply 20.5% move in share price post-earnings
Pre-earnings options volume in Mineralys Therapeutics (MLYS) Inc is normal with calls leading puts 42:1. Implied volatility suggests the market is anticipating a move near 20.5%, or 0c, after results…
Mineralys Therapeutics Inc options imply 16.5% move in share price post-earnings
Pre-earnings options volume in Mineralys Therapeutics (MLYS) Inc is 28.3x normal with puts leading calls 2:1. Implied volatility suggests the market is anticipating a move near 16.5%, or 0c, after…
Mineralys Therapeutics Inc options imply 21.7% move in share price post-earnings
Pre-earnings options volume in Mineralys Therapeutics (MLYS) Inc is normal with puts leading calls 56:1. Implied volatility suggests the market is anticipating a move near 21.7%, or 0c, after results…
Mineralys Therapeutics Inc options imply 13.2% move in share price post-earnings
Pre-earnings options volume in Mineralys Therapeutics (MLYS) Inc is normal with calls leading puts 6:1. Implied volatility suggests the market is anticipating a move near 13.2%, or 0c, after results…
Mineralys Therapeutics Inc call volume above normal and directionally bullish
Bullish option flow detected in Mineralys Therapeutics (MLYS) Inc with 1,300 calls trading, 3x expected, and implied vol increasing almost 6 points to 90.78%. Jun-26 35 calls and Mar-26 40…